Biopharma news, November 18, 2026
4 stories
In this digest: Approval 2 · Pivotal readout 1 · Licensing & partnership 1
Top stories
Gevalka Approved in EU
The European Commission approved Gevalka for adults with ALK-positive advanced non-small cell lung cancer. The approval was based on the phase 3 eXalt3 study, in which median progression-free survival was 25.8 months with ensartinib versus 12.7 months in the control group. Betta and its subsidiary Xcovery developed ensartinib, which has also been approved in China and the United States; an exclusive licensing agreement with Mankind Pharma covers India.
Source types: Press release
Dayvigo Korea Launch Planned
A sleep specialist reported that Dayvigo maintained improvements in insomnia outcomes for one year in SUNRISE 2, without evidence of tolerance, rebound insomnia or withdrawal symptoms after discontinuation.
Read more about Dayvigo Korea Launch Planned
In SUNRISE 1, Dayvigo shortened time to sleep onset more than extended-release zolpidem in older adults. Other studies discussed nighttime balance, next-morning driving and breathing safety. South Korea approved Dayvigo in June for adults with difficulty falling or staying asleep. Eisai Korea plans a late-November launch and will co-promote it with SK Chemicals.
Source types: News article
Pfizer Licenses Starna CAR-T Programs
Pfizer licensed three pre-IND in vivo CAR-T programs for autoimmune diseases from Starna Therapeutics, with exclusive rights outside Greater China.
Read more about Pfizer Licenses Starna CAR-T Programs
Starna will receive $330 million upfront and is eligible for up to $2.3 billion in development and commercial milestones, plus royalties. Pfizer will lead development outside Greater China, plans to manufacture initial clinical trial product in the United States, and has options to expand its territorial rights.
Source types: Press release
News in brief
FDA Clears Masimo smartSedLine
Read more about FDA Clears Masimo smartSedLine
Masimo received FDA 510(k) clearance for smartSedLine, a brain function monitoring solution for use during anesthesia. Its enhanced Patient State Index algorithm is designed to respond faster during induction and provide more stable readings under low EEG power. The new module and sensor work with compatible monitors, including Masimo Root, and can be used alongside O3 Regional Oximetry.
Source types: Press release
Sources are available to Gosset users. Log in to see them.
All digests
- November 17, 2026 5 stories
- November 16, 2026 3 stories
- November 15, 2026 4 stories
- November 14, 2026 5 stories
- November 13, 2026 5 stories
- November 12, 2026 10 stories
- November 11, 2026 10 stories
- November 10, 2026 10 stories
- November 9, 2026 10 stories
- November 8, 2026 9 stories
- November 7, 2026 7 stories
- November 6, 2026 10 stories
- November 5, 2026 10 stories